PsymaTalk: Gordon Gochenauer on ASCO 2018 - Part 2

with Gordon Gochenauer, Oncology lead at Psyma USA

In this second post, Gordon Gochenauer, Psyma’s Oncology Practice Lead, shares his thoughts on the future of immunotherapy combinations based on recent results of IDO trials to be presented at ASCO 2018.

Contact us to find out more about our Oncology Practice.

 

Psyma Group AG

Rueckersdorf/Nuremberg Germany
Phone: +49 (0)911 99574-0
E-Mail: info@psyma.com